These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26004402)

  • 1. A Multitargeted Treatment Approach for Anemia and Cachexia in Metastatic Castration-Resistant Prostate Cancer.
    Macciò A; Gramignano G; Madeddu C
    J Pain Symptom Manage; 2015 Aug; 50(2):e1-4. PubMed ID: 26004402
    [No Abstract]   [Full Text] [Related]  

  • 2. Simultaneous chylothorax and chylous ascites in a patient with castration-resistant prostate cancer after docetaxel chemotherapy: An unusual manifestation.
    Shimizu Y; Kanamaru S; Ito N
    Int J Urol; 2015 Jun; 22(6):614. PubMed ID: 25854536
    [No Abstract]   [Full Text] [Related]  

  • 3. Renal impairment in prostate cancer: A close look is important.
    Naronha V; Pinninti R; Joshi A; Prabhash K
    Indian J Cancer; 2015; 52(1):113. PubMed ID: 26837995
    [No Abstract]   [Full Text] [Related]  

  • 4. Advances in systemic therapies for metastatic castration-resistant prostate cancer.
    Pant MK; Abughaban A; Aragon-Ching JB
    Future Oncol; 2014 Nov; 10(14):2213-26. PubMed ID: 25471035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
    Dreicer R
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-5. PubMed ID: 26352772
    [No Abstract]   [Full Text] [Related]  

  • 6. Emerging therapies in castration resistant prostate cancer.
    Thoreson GR; Gayed BA; Chung PH; Raj GV
    Can J Urol; 2014 Apr; 21(2 Supp 1):98-105. PubMed ID: 24775731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer.
    Goyal J; Pond GR; Galsky MD; Hendricks R; Small A; Tsao CK; Sonpavde G
    Urol Oncol; 2014 Jan; 32(1):36.e27-34. PubMed ID: 23685020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding cachexia in patients with cancer.
    Holmes S
    Nurs Stand; 2011 Jan 26-Feb 1; 25(21):47-56; quiz 58. PubMed ID: 21329133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life in men with metastatic castration-resistant prostate cancer.
    Gee A; Challapalli A; Bahl A
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):941-9. PubMed ID: 26512743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current status and future direction of the treatment of CRPC (castration resistant prostate cancer)].
    Akaza H
    Nihon Rinsho; 2014 Dec; 72(12):2108-15. PubMed ID: 25518342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The E2F1/DNMT1 axis is associated with the development of AR negative castration resistant prostate cancer.
    Valdez CD; Kunju L; Daignault S; Wojno KJ; Day ML
    Prostate; 2013 Dec; 73(16):1776-85. PubMed ID: 24038143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
    Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C
    Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential therapies in castration-resistant prostate cancer.
    Buonerba C; Di Lorenzo G
    Future Oncol; 2014 Feb; 10(2):153-5. PubMed ID: 24490599
    [No Abstract]   [Full Text] [Related]  

  • 15. Rational treatment of anemias in malignant diseases.
    Lynch EC; Alfrey CP; Hettig RA
    Tex Med; 1971 Dec; 67(12):64-74. PubMed ID: 5129500
    [No Abstract]   [Full Text] [Related]  

  • 16. A Patient With Pancytopenia, Intractable Epistaxis, and Metastatic Prostate Cancer: How Correct Diagnosis of Primary Hyperfibrinolysis Helps to Stop the Bleeding.
    Jafri MA; Cohen JV; Much MA; Petrylak DP; Podoltsev NA
    Clin Genitourin Cancer; 2016 Oct; 14(5):e545-e548. PubMed ID: 27320762
    [No Abstract]   [Full Text] [Related]  

  • 17. Non-metastatic castration-resistant prostate cancer (CPRCM0), an old scenario with renewed clinical interest.
    Morote J; Planas J; Maldonado X; Carles J
    Actas Urol Esp; 2014 Sep; 38(7):419-20. PubMed ID: 24866537
    [No Abstract]   [Full Text] [Related]  

  • 18. Accelerated muscle and adipose tissue loss may predict survival in pancreatic cancer patients: the relationship with diabetes and anaemia.
    Di Sebastiano KM; Yang L; Zbuk K; Wong RK; Chow T; Koff D; Moran GR; Mourtzakis M
    Br J Nutr; 2013 Jan; 109(2):302-12. PubMed ID: 23021109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin attenuates cachectic events and decreases production of interleukin-6, a cachexia-inducing cytokine.
    Kanzaki M; Soda K; Gin PT; Kai T; Konishi F; Kawakami M
    Cytokine; 2005 Dec; 32(5):234-9. PubMed ID: 16338141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should the Urologist Treat Castration Resistant Prostate Cancer? No.
    Petrylak DP
    J Urol; 2015 Aug; 194(2):286-7. PubMed ID: 25986508
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.